Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities and Persons Closely Associated
November 29, 2024 04:00 ET
|
Oculis Holding AG
ZUG, Switzerland, Nov. 29, 2024 (GLOBE NEWSWIRE) -- The attached notifications relate to the vesting of earnout shares and associated removal of restrictions on these ordinary shares.
...
Oculis Publishes Notification of Transaction by Person Discharging Managerial Responsibilities
November 27, 2024 04:15 ET
|
Oculis Holding AG
ZUG, Nov. 27, 2024 (GLOBE NEWSWIRE) -- The attached notification relates to a one-time equity incentive award issued to a director of the Company for his independent services as a consultant to the...
Oculis to Present at the Stifel 2024 Healthcare Conference
November 13, 2024 04:00 ET
|
Oculis Holding AG
ZUG, Switzerland, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today...
Oculis to Present at the Stifel 2024 Healthcare Conference
November 13, 2024 04:00 ET
|
Oculis Holding AG
ZUG, Switzerland, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today...
Oculis Reports Q3 2024 Financial Results and Provides Company Updates
November 07, 2024 04:00 ET
|
Oculis Holding AG
Significant advancement on product portfolio, including enrollment in the OCS-01 DIAMOND Phase 3 program in DME and OCS-05 Phase 2 ACUITY trial in acute optic neuritis (AON) with topline readout...
Oculis birtir uppgjör fyrir þriðja ársfjórðung 2024 og kynnir nýjustu áfanga í rekstri félagsins
November 07, 2024 04:00 ET
|
Oculis Holding AG
ZUG, Sviss, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Veruleg framvinda þróunarlyfja, þar á meðal innritun í OCS-01 DIAMOND fasa 3 rannsókninni á sjónhimnubjúg í sykursýki (DME) og OCS-05 fasa 2 ACUITY...
Oculis Reports Q3 2024 Financial Results and Provides Company Updates
November 07, 2024 04:00 ET
|
Oculis Holding AG
ZUG, Switzerland, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Significant advancement on product portfolio, including enrollment in the OCS-01 DIAMOND Phase 3 program in DME and OCS-05 Phase 2 ACUITY...
Oculis Accelerates Enrollment in both DIAMOND Phase 3 Trials of OCS-01 in Diabetic Macular Edema and Expands its DIAMOND Program Committees
October 21, 2024 13:04 ET
|
Oculis Holding AG
ZUG, Switzerland, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Phase 3 DIAMOND-1 and DIAMOND-2 trials enrollment of OCS-01 in diabetic macular edema (DME) accelerated with great momentumDIAMOND program...
Oculis Accelerates Enrollment in both DIAMOND Phase 3 Trials of OCS-01 in Diabetic Macular Edema and Expands its DIAMOND Program Committees
October 21, 2024 04:00 ET
|
Oculis Holding AG
Phase 3 DIAMOND-1 and DIAMOND-2 trials enrollment of OCS-01 in diabetic macular edema (DME) accelerated with great momentumDIAMOND program committees expanded with globally renowned retina experts If...
Oculis’ DIAMOND Phase 3 Program in Diabetic Macular Edema to be Presented at Innovate Retina and Eyecelerator 2024
October 15, 2024 04:00 ET
|
Oculis Holding AG
ZUG, Switzerland, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today...